GlaxoSmithKline on Sunday said its board rejected a request from the Arab Company for Drug Industries & …
GlaxoSmithKline
-
-
FeatureIndustry & TradeTech/AI
Hikma, GlaxoSmithKline cease talks over potential deal to buy Egypt, Tunisia assets
GlaxoSmithKline said on Thursday that its majority shareholder Glaxo Group Limited and Hikma Pharmaceuticals have agreed to …
-
Egypt’s Rameda Pharmaceutical said in a bourse filling on Tuesday it had withdrawn its proposal to acquire …
-
FeatureIndustry & TradeTech/AI
GlaxoSmithKline in talks with Hikma to sell Egypt stake, rules out talks with Rameda
by Islam salahby Islam salahGlaxoSmithKline will focus its efforts and resources on discussing the sale of its stake in Egypt with …
-
Egypt’s Rameda Pharmaceutical said on Tuesday it had submitted a non-binding letter of intent to purchase GlaxoSmithKline’s …
-
FeatureIndustry & TradeTech/AI
Acdima expressed interest in buying majority stake in GlaxoSmithKline Egypt
Arab Company for Drug Industries and Medical Appliances (Acdima – Egypt) expressed an interest in acquiring GlaxoSmithKline’s …
-
FeatureIndustry & TradeTech/AI
GlaxoSmithKline allows Hikma Pharmaceuticals due diligence on Egypt, Tunisia assets
GlaxoSmithKline said on Wednesday its board of directors has allowed Hikma Pharmaceuticals, which is interested in buying …
-
Hikma Pharmaceuticals announced on Tuesday plans to buy GlaxoSmithKline’s stake in some assets including the drugmaker’s pharmaceutical, …
-
A coronavirus vaccine being developed by Sanofi in partnership with Britain’s GlaxoSmithKline is expected to be priced …
-
Industry & TradeTech/AI
Sanofi ready to produce over 600 million coronavirus vaccine doses if proven successful
French drugmaker Sanofi is ready to produce up to 600 million doses of its coronavirus vaccine next year if …